drugset / Trial / NCT00657891

The Effect of Xolair (Omalizumab) on Allergy Blood Cells

NCT00657891

RandomizedParallel-groupTriple-blindBasic science

Summary

We are studying Xolair (omalizumab) to see it's effect on allergic blood cells. The blood tests will be done in a test tube to see if they react differently before and after treatment. The blood cells will be mixed with to whatever the person is allergic.

Timeline

Start
2007-03
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Omalizumab Monoclonal antibody 0.016 mg/kg Subcutaneous

Indications